Tairāwhiti faces measles risk with low immunisation rates
Only four regions—Canterbury, Southern, West Coast, and Capital & Coast — have reached the 84% 'milestone' figure set for the 2024–2025 period.
Health experts also warn that many adults born between 1969 and 2004 may not be fully protected with the full two-dose measles vaccination, now the recommended dosage.
A Tairāwhiti senior doctor, who asked not to be named, told the Gisborne Herald that health services in the region were already under pressure.
'So how would we manage the additional demand from a large measles outbreak?' he said.
'Prevention is key. Contact tracing will only be important initially to stop the spread. Vaccination will be more important to limit the extent of an outbreak.'
The doctor said a desktop exercise with education and health partners on March 28 had been conducted to prepare for the spread of measles and increase local capacity for contact tracing and vaccination.
A Tairāwhiti nurse, who also asked not to be identified, told the Gisborne Herald that children could potentially die because of low immunisation rates.
It was a nationwide issue and small children were the most at risk of serious diseases, she said.
'The importance of vaccination needs to be stressed.'
Acting clinical director, protection, National Public Health Service, Dr Matt Reid, in a statement, said there was much concern about a potential measles outbreak in NZ, given the rapid rise of measles cases overseas and low immunisation rates here.
'There are several regions we are particularly concerned about due to especially low immunisation rates.
'This includes Tairāwhiti, Lakes and Northland districts, which have lower immunisation coverage... less than 70%.
'The aim is for all districts to reach 85% by the end of the financial year, which still has two quarters remaining.
Reid said there were no measles cases in the country, 'but in preparation for the possibility of a case being identified in NZ, we've reminded people of the importance of immunisation, particularly if they are travelling overseas.
'If you're not immune to measles, or you're not sure if you've had two doses of the vaccine, talk to your healthcare provider about getting vaccinated.
'It is safe to have extra doses of the MMR vaccine even if you are already protected.'
The MMR vaccine is free for everyone under 18 years old, regardless of visa status.
'For those aged over 18, the vaccine is free if you're eligible for free healthcare in NZ.
'The vaccine is safe and very effective.'
After two doses, 99% of people are protected from measles.
The Public Health Communication Centre's Briefing recommended three immediate actions to prevent an epidemic.
Catch-up MMR immunisation for those aged 15 months to 9 years without documented receipt of two doses of MMR vaccine. Priority should be given to existing immunisation requirements for primary schools and pre-schools to reach a 95% plus coverage target. It is these institutions that particularly drive the spread in the community.
Improved communication to travellers about measles risk. For residents even more than visitors, as those returning home are more likely to import the virus.
Rethink the country's response to new measles cases arising in the community to have a stronger immunisation component.
The United States is enduring the largest measles outbreak in 25 years, with 935 confirmed measles cases as of May 1.
Three outbreaks in Canada, Mexico and the US account for about 2300 measles cases across the World Health Organisation's six-country Americas region.
As of May 1, 59 measles cases had been reported across Australia, compared to 57 cases for all of 2024.
Every state and territory, except Tasmania and the Australian Capital Territory, has recorded at least one case.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
19 hours ago
- Scoop
Cancer, Measles And Allergic Disease Research Funded In Latest HRC Grants Round
Press Release – Malaghan Institute of Medical Research Director Professor Kjesten Wiig says receiving three major grants from the Health Research Council at a time of heightened funding constraints is significant and recognises the calibre and relevance of the Malaghan Institutes science. The Malaghan Institute has been awarded three Health Research Council grants, totalling $7.4M over five years, to improve cancer immunotherapies, protect vulnerable populations from measles outbreaks and investigate new therapeutic targets for eczema. Director Professor Kjesten Wiig says receiving three major grants from the Health Research Council at a time of heightened funding constraints is significant and recognises the calibre and relevance of the Malaghan Institute's science. 'These investments not only reflect confidence in the Malaghan's research across cancer, allergic and infectious diseases, but also the real-world impact of our work on the health of New Zealanders.' Faster CARs: Overcoming exhaustion to enhance cancer immunotherapies Building on the Malaghan Institute's ground-breaking CAR T-cell programme, the Perret team in the Weinkove Laboratory has recieved a $1.2 million project grant over three years to improve on this life-saving treatment. 'In Aotearoa's first CAR T-cell trial, our novel CAR T-cell therapy has shown promising safety and efficacy in people with relapsed lymphomas,' says Dr Rachel Perret. 'However, a known limitation of CAR T-cell therapies is that in some cases, cancers fail to respond, or relapse. This may be due to exhaustion of CAR T-cells during manufacture or inside the patient, due to a immunosuppressive environment around the tumour.' Cells, like people, can become exhausted if overworked or overstimulated, becoming less and less able to perform. However, unlike people, CAR T-cells can be tweaked to block the genes that signal this exhaustion, allowing them to continue fighting cancer for longer – which should also improve patient outcomes. 'This project will re-engineer CAR T-cells to silence genes linked to exhaustion and re-develop CAR T-cell manufacturing processes to enhance CAR T- cell fitness and shorten manufacturing times,' says Dr Perret. 'We expect the results to be applicable to many cancer types, and to be readily translated for the benefit of New Zealanders within our CAR T-cell clinical trial programme.' Providing equal protection for everyone against measles Herd immunity is how we as a population protect those who are immunocompromised or otherwise unable to get vaccinated (such as very young infants) against potentially life-threatening viruses like measles. When enough of the population are vaccinated (over 95% in the case of measles), this herd immunity effectively prevents viruses from spreading to our most vulnerable whānau. 'While the current measles, mumps and rubella (MMR) vaccine is highly effective at protecting vaccinated individuals against these viruses, current vaccination rates are not high enough to provide this essential herd immunity to protect those who cannot be vaccinated,' says paediatric immunologist Dr Kuang Hsiao from Waipapa Taumata Rau, University of Auckland, who is part of the research team. The MMR vaccine cannot be used in people with severely impaired immune systems and is not recommended in pregnant people. Also, MMR is less effective in infants, so is not routinely recommended before 12 months of age. In addition, Māori and Pacific communities are overrepresented among these vulnerable groups. For these populations, alternate protective options are required to prevent a measles outbreak. 'Evidence has shown that mRNA-based vaccines can be effective in these vulnerable individuals,' says the Malaghan's Professor Ian Hermans. 'With an international team involving clinicians, immunologists and Māori and Pacific researchers, we will develop an mRNA-based measles vaccine to give to vulnerable individuals in the event of an outbreak.' The research has been awarded an HRC Programme Grant, worth $5M over five years, and will bring together multiple organisations including the Malaghan, representing diverse areas of expertise and combining both fundamental research and public health. 'As part of this work, we will explore with Māori and Pacific communities' perceptions and beliefs about mRNA-based vaccines to support equitable access to the vaccine,' says Dr Hermans. Investigating novel treatment targets for atopic dermatitis Atopic dermatitis, or eczema, is a chronic skin allergic disease that affects a significant proportion of New Zealand's population. The disease can have a significant negative impact on a person's livelihood with symptoms varying from persistent itchiness, redness, dryness and inflammation. Current treatment options are largely immunosuppressants such as corticosteroids, which can cause side effects. While these treatments can help manage symptoms there are currently no effective therapies to prevent the disease from developing and relapsing. At the cellular level, one hallmark of atopic dermatitis is the chronic infiltration and persistence of immune cells called tissue resident memory T-cells. Normally, these cells are vital for protecting the skin from invading pathogens, but for individuals with atopic dermatitis these cells also contribute to the disease by promoting recurring inflammation even after the allergen has been cleared from the skin. The project, which has been awarded $1.2 million over three years, will be led by Dr Sotaro Ochiai, a Senior Research Fellow in the Ronchese Laboratory. The team will focus on better understanding these tissue resident memory T-cells identifying key genes and biological pathways that are essential for the establishment and maintenance of these cells in the skin. 'By understanding these mechanisms, we aim to identify new therapeutic targets to disrupt tissue resident memory T-cell survival or function and improve quality of life for those affected by this persistent and distressing condition,' says Dr Ochiai.
Otago Daily Times
05-08-2025
- Otago Daily Times
Dengue fever cases surging in New Zealand
The Asian tiger mosquito is one of the vectors responsible for transmitting dengue fever. Photo: SCIENCE PHOTO LIBRARY Doctors are being warned to be on alert for people with symptoms of dengue fever as the number of cases in New Zealand surges. National Public Health Service physician Dr Sharon Sime told Midday Report public health teams were also seeing a surge in cases among people returning home after picking up the illness overseas. Dengue cases in the Pacific are at their highest level in almost a decade. Samoa is particularly affected with more than 2000 cases reported and multiple deaths since an outbreak was declared in April. In New Zealand, there have been 208 cases of dengue nationally in the year to date. Of those, 103 were recorded in Auckland this year, double the amount recorded for all of 2024. Around a third of the cases so far this year have also ended up being hospitalised. "What's different with dengue fever is many people with dengue don't have symptoms," Dr Sime said. "So, the ones that we diagnose is likely an under representation of the number of cases." New Zealand does not have mosquitoes able to transmit dengue, so you can't get the disease in New Zealand, Dr Sime said. While you cannot catch dengue fever from another person, you can get it from infected mosquitoes in an area or region that has dengue, and there is no available vaccine in New Zealand. "At the moment, our climate wouldn't work for the particular type of mosquito that carries dengue. We do also have a monitoring programme at our airports and our ports where we are constantly monitoring for any imported mosquito, just so that we would get an early warning of any chance of these mosquitoes surviving in New Zealand," Dr Sime said. Symptoms of dengue fever include a sudden high fever, intense headache, pain behind the eyes, muscle and joint pain, tiredness, nausea, vomiting and a fine rash, which may be itchy and usually begins on the extremities, but spares the palms and soles of the feet. Many people infected with dengue will only have mild symptoms, but a small number of people may get severe dengue and require hospital care. Dr Susan Jack, National Clinical Director for National Public Health Service, said people over 60 years old and children aged 10 and under were also at greater risk of severe illness from dengue. Dr Jack said anyone travelling outside New Zealand to an area with dengue can protect themselves by: - Staying or sleeping in well-screened locations, or under mosquito nets - Keeping screens on doors and windows closed when indoors - Wearing light-coloured protective clothing, including, hats, long sleeves and trousers when outdoors - Wearing a repellent cream or spray containing less than 35 percent diethyltoluamide (DEET) when outdoors - Avoiding places where mosquitoes are most active, such as swampy areas or places with standing water.
RNZ News
05-08-2025
- RNZ News
Doctors on alert as dengue fever cases surge among people returning from overseas
The Asian tiger mosquito is one of the vectors responsible for transmitting dengue fever. Photo: SCIENCE PHOTO LIBRARY Doctors are being warned to be on alert for people with symptoms of dengue fever as the number of cases in New Zealand surges. National Public Health Service physician Dr Sharon Sime told Midday Report public health teams are also seeing a surge in cases among people returning home after picking up the illness overseas. Dengue cases in the Pacific are at their highest level in almost a decade, with Samoa particularly affected with more than 2000 cases reported and multiple deaths since an outbreak was declared in April. In New Zealand, there have been 208 cases of dengue nationally in the year to date. Of those, 103 cases were recorded in Auckland this year, double the amount recorded for all of 2024. Around a third of the cases so far this year have also ended up being hospitalised. "What's different with dengue fever is many people with dengue don't have symptoms," Dr Sime said. "So, the ones that we diagnose is likely an under representation of the number of cases." New Zealand does not have mosquitoes able to transmit dengue, so you can't get the disease in New Zealand, Dr Sime said. While you cannot catch dengue fever from another person, you can get it from infected mosquitoes in an area or region that has dengue, and there is no available vaccine in New Zealand. "At the moment, our climate wouldn't work for the particular type of mosquito that carries dengue. We do also have a monitoring programme at our airports and our ports where we are constantly monitoring for any imported mosquito, just so that we would get an early warning of any chance of these mosquitoes surviving in New Zealand," Dr Sime said. Symptoms of dengue fever include a sudden high fever, intense headache, pain behind the eyes, muscle and joint pain, tiredness, nausea, vomiting and a fine rash, which may be itchy and usually begins on the extremities, but spares the palms and soles of the feet. Many people infected with dengue will only have mild symptoms, but a small number of people may get severe dengue and require hospital care. Dr Susan Jack, National Clinical Director for National Public Health Service, said people over 60 years old and children aged 10 and under are also at greater risk of severe illness from dengue. Dr Jack said if you're travelling outside Aotearoa New Zealand to an area with dengue, protect yourself by: Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
